Increased gastric pH and the bioavailability of fluconazole and ketoconazole.
about
Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazolePharmacokinetics of two multiple-dosing regimens of D0870 in human immunodeficiency virus-positive patients: a phase I studyIn vivo interaction of ketoconazole and sucralfate in healthy volunteersEffects of the antifungal agents on oxidative drug metabolism: clinical relevance.Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin.Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.Human pharmacogenomic variations and their implications for antifungal efficacy.Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infectionDidanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infectionsEffect of cyclodextrin on the pharmacology of antifungal oral azoles.Pharmacokinetics and bioavailability of fluconazole in patients with AIDS.Fluconazole for the treatment of candidiasis: 15 years experience.Drug interactions: part II.Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy menSystematic review: impaired drug absorption related to the co-administration of antisecretory therapy.Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria.Interactions between antifungal and antiretroviral agents.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Consequences of gastrointestinal surgery on drug absorption.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Antibiotic Dosing in Patients With Acute Kidney Injury: "Enough But Not Too Much".Acid suppressing therapy as a risk factor for Candida esophagitis.Update on drug interactions with azole antifungal agents.Azole resistance in Candida.Advancing in-vitro drug precipitation testing: new process monitoring tools and a kinetic nucleation and growth model.In vitro analysis of the interaction between sucralfate and ketoconazole.Considerations in choice of a clinical endpoint for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).Fluconazole-induced symptomatic phenytoin toxicity.Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients.Considerations for using ketoconazole in solid organ transplant recipients receiving cyclosporine immunosuppression.Current issues in onychomycosis.Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers.Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole.Gastric function in the elderly: effects on absorption of ketoconazole.Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus.Inhibition of antifungal therapy by gastric acid suppressants.Oral Contraceptives after Bariatric Surgery.Integrating biopharmaceutics risk assessment and in vivo absorption model in formulation development of BCS class I drug using the QbD approach.Risk assessment for extending the Biopharmaceutics Classification System-based biowaiver of immediate release dosage forms of fluconazole in adults to the paediatric population.Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test.
P2860
Q24676913-878FA77B-BD21-4537-912B-404345758A1AQ33692789-A7AD7031-3450-43B2-B9B4-B8F885996647Q33749319-B7E58CE9-BC49-444E-ACC5-0283C9F247C4Q33858325-74415410-6DC5-489B-8CB0-28D3BECCED03Q34105081-86F55DB4-7C06-4349-9456-24ADD9836543Q34437719-83759580-D876-4A4A-8D35-6FD03AF15A6BQ35070838-99CDDED4-4DB1-4EF0-B1D3-868AD13A38EFQ35117518-BE8BB6FC-1D71-4E7F-BBB3-A8D1832FA220Q35123292-FA5F3669-FE24-435D-82FA-37D4BA19FC15Q35826467-E07A7C5D-6DDD-4C78-BE28-8A648919B075Q35897483-E5354F1F-1954-4ACE-9708-C046A3A00F56Q35917407-5DCC7DF1-CA18-456C-8BEE-66EE68DF3959Q36235775-FFA2AC93-A2A0-4ECB-AE5C-7BD3221FB681Q36489989-2457A52B-DAB8-475C-94A2-0006F7FA2C21Q37419478-CEE00807-5714-4AE3-BDBC-95E9CF7BFE74Q37624513-4E448B09-197D-4087-B382-0E01D0FA4808Q37719545-E917992B-F053-4097-91C0-06DDD68D1CF3Q37904672-CF5182A0-BA24-46A1-A961-CCFD7F43D367Q38120133-8FAAD7F1-41C3-480F-8C38-A3706A510B69Q38193337-D5A6DDFD-8300-4BB5-AD78-AC6E5539F52CQ38261172-5B14A1A0-3C7E-49E9-911A-B6E8011043A3Q38400673-8689CC86-18E0-44AA-BB45-A2D2FF518F30Q38549824-8B108BCE-02BF-4991-907F-A6BCA6F47E7DQ38970335-37265187-2BD3-4477-8676-48A84229614AQ39729707-88A9862E-3580-492F-8EFF-EA3894210C2FQ40285026-1D569ECF-DE8E-4FD7-A2D0-4C0B3E8042C2Q40586114-8CA7168F-1A57-48E5-A926-3EDEDF0EC8FEQ40748053-19056356-379B-4E69-B60A-E05BD4F9BCBEQ41284012-5E42C2CE-414E-49A3-9AF8-418C3E4FB4C2Q41503505-578BA320-05B6-4045-B1EA-046CE80D8FB8Q41718745-35F577E7-60D3-465D-AEB3-73D9C8AE7B83Q42659552-8FFD479E-64DD-4481-8010-3F3DE60972F8Q42673742-99884513-CE1A-4911-B5A1-749C44A673BCQ44582906-93E5790C-F030-4BB3-80CA-9078DFD1AC17Q45777843-F1F83CAC-2479-42C0-9B91-8B8173D5A37CQ46492453-B8338E70-D171-47C6-B5B9-F5541AF22FCEQ47108031-44C40051-5B5A-4726-B847-5F1EB2DA76F3Q47592497-209FA28E-6A8A-4BA4-8071-2BD654E98489Q50593909-D1C1E5F9-F4DA-402A-B10B-A343C83CD646Q52668360-A6A3BD9C-3B1F-4CDE-A467-059821993367
P2860
Increased gastric pH and the bioavailability of fluconazole and ketoconazole.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Increased gastric pH and the bioavailability of fluconazole and ketoconazole.
@en
Increased gastric pH and the bioavailability of fluconazole and ketoconazole.
@nl
type
label
Increased gastric pH and the bioavailability of fluconazole and ketoconazole.
@en
Increased gastric pH and the bioavailability of fluconazole and ketoconazole.
@nl
prefLabel
Increased gastric pH and the bioavailability of fluconazole and ketoconazole.
@en
Increased gastric pH and the bioavailability of fluconazole and ketoconazole.
@nl
P2093
P1476
Increased gastric pH and the bioavailability of fluconazole and ketoconazole.
@en
P2093
D'Andrea DT
Florentino BM
Gardner MJ
Goldstein H
Hilligoss DM
Schentag JJ
P304
P356
10.7326/0003-4819-114-9-755
P407
P577
1991-05-01T00:00:00Z